Operable gastric cancer diagnosed soon after implantation of a coronary drug-eluting stent: How to manage?

D. Bona, A. Aiolfi, S. Picozzi, B. Rubino, L. Bonavina

Research output: Contribution to journalArticle

Abstract

Background: An increasing number of patients receive dual antiplatelet therapy following percutaneous coronary interventions. The management of these patients is controversial when urgent noncardiac surgery is required, considering the serious cardiological consequences if such drugs are withdrawn and a high risk of bleeding if they are continued. "Bridging" antiplatelet therapy with tirofiban, a short-acting glycoprotein IIb/IIIa receptor blocker, was used to manage a patient recently implanted with a drug-eluting stent and still on dual antiplatelet therapy, who underwent laparoscopic gastrectomy for gastric carcinoma. Methods Therapy with prasugrel was discontinued 5 days before the surgery and intravenous infusion of tirofiban was started at a dose of 0.4 ìg Kg. 1 min. 1 over 30 min, followed by 0.1 ìg Kg. 1 min. 1. The infusion was stopped 6 h before the surgery. Two hours after the surgical procedure, the same treatment schedule with tirofiban already given preoperatively, including the 30 min bolus, was applied. Prasugrel therapy was resumed 180 h after the surgery. Results: The postoperative course was uneventful. No bleeding or thrombotic events occurred, and the patient was safely discharged home 2 weeks after the surgical procedure. Conclusions There is a lack of precise guidelines for patients recently implanted with drug-eluting stents. A multidisciplinary approach and close collaboration among surgeons, anesthesiologists and cardiologists is required, especially when the surgical procedure cannot be postponed. The "bridging" pharmacological protocol was safe and effective after laparoscopic gastrectomy for carcinoma.

Original languageEnglish
Pages (from-to)341-344
Number of pages4
JournalEuropean Surgery - Acta Chirurgica Austriaca
Volume44
Issue number5
DOIs
Publication statusPublished - Oct 2012

Fingerprint

Drug-Eluting Stents
tirofiban
Stomach Neoplasms
Gastrectomy
Therapeutics
Hemorrhage
Carcinoma
Platelet Glycoprotein GPIIb-IIIa Complex
Percutaneous Coronary Intervention
Ambulatory Surgical Procedures
Intravenous Infusions
Stomach
Appointments and Schedules
Pharmacology
Guidelines
Pharmaceutical Preparations

Keywords

  • Drug-eluting stent
  • Dual antiplatelet therapy
  • Intraoperative bleeding
  • Laparoscopic gastrectomy
  • Stent thrombosis

ASJC Scopus subject areas

  • Surgery

Cite this

Operable gastric cancer diagnosed soon after implantation of a coronary drug-eluting stent : How to manage? / Bona, D.; Aiolfi, A.; Picozzi, S.; Rubino, B.; Bonavina, L.

In: European Surgery - Acta Chirurgica Austriaca, Vol. 44, No. 5, 10.2012, p. 341-344.

Research output: Contribution to journalArticle

@article{df69bbeab24646daa41fd6e21714d943,
title = "Operable gastric cancer diagnosed soon after implantation of a coronary drug-eluting stent: How to manage?",
abstract = "Background: An increasing number of patients receive dual antiplatelet therapy following percutaneous coronary interventions. The management of these patients is controversial when urgent noncardiac surgery is required, considering the serious cardiological consequences if such drugs are withdrawn and a high risk of bleeding if they are continued. {"}Bridging{"} antiplatelet therapy with tirofiban, a short-acting glycoprotein IIb/IIIa receptor blocker, was used to manage a patient recently implanted with a drug-eluting stent and still on dual antiplatelet therapy, who underwent laparoscopic gastrectomy for gastric carcinoma. Methods Therapy with prasugrel was discontinued 5 days before the surgery and intravenous infusion of tirofiban was started at a dose of 0.4 {\`i}g Kg. 1 min. 1 over 30 min, followed by 0.1 {\`i}g Kg. 1 min. 1. The infusion was stopped 6 h before the surgery. Two hours after the surgical procedure, the same treatment schedule with tirofiban already given preoperatively, including the 30 min bolus, was applied. Prasugrel therapy was resumed 180 h after the surgery. Results: The postoperative course was uneventful. No bleeding or thrombotic events occurred, and the patient was safely discharged home 2 weeks after the surgical procedure. Conclusions There is a lack of precise guidelines for patients recently implanted with drug-eluting stents. A multidisciplinary approach and close collaboration among surgeons, anesthesiologists and cardiologists is required, especially when the surgical procedure cannot be postponed. The {"}bridging{"} pharmacological protocol was safe and effective after laparoscopic gastrectomy for carcinoma.",
keywords = "Drug-eluting stent, Dual antiplatelet therapy, Intraoperative bleeding, Laparoscopic gastrectomy, Stent thrombosis",
author = "D. Bona and A. Aiolfi and S. Picozzi and B. Rubino and L. Bonavina",
year = "2012",
month = "10",
doi = "10.1007/s10353-012-0158-8",
language = "English",
volume = "44",
pages = "341--344",
journal = "Acta Chirurgica Austriaca",
issn = "0001-544X",
publisher = "Springer Wien",
number = "5",

}

TY - JOUR

T1 - Operable gastric cancer diagnosed soon after implantation of a coronary drug-eluting stent

T2 - How to manage?

AU - Bona, D.

AU - Aiolfi, A.

AU - Picozzi, S.

AU - Rubino, B.

AU - Bonavina, L.

PY - 2012/10

Y1 - 2012/10

N2 - Background: An increasing number of patients receive dual antiplatelet therapy following percutaneous coronary interventions. The management of these patients is controversial when urgent noncardiac surgery is required, considering the serious cardiological consequences if such drugs are withdrawn and a high risk of bleeding if they are continued. "Bridging" antiplatelet therapy with tirofiban, a short-acting glycoprotein IIb/IIIa receptor blocker, was used to manage a patient recently implanted with a drug-eluting stent and still on dual antiplatelet therapy, who underwent laparoscopic gastrectomy for gastric carcinoma. Methods Therapy with prasugrel was discontinued 5 days before the surgery and intravenous infusion of tirofiban was started at a dose of 0.4 ìg Kg. 1 min. 1 over 30 min, followed by 0.1 ìg Kg. 1 min. 1. The infusion was stopped 6 h before the surgery. Two hours after the surgical procedure, the same treatment schedule with tirofiban already given preoperatively, including the 30 min bolus, was applied. Prasugrel therapy was resumed 180 h after the surgery. Results: The postoperative course was uneventful. No bleeding or thrombotic events occurred, and the patient was safely discharged home 2 weeks after the surgical procedure. Conclusions There is a lack of precise guidelines for patients recently implanted with drug-eluting stents. A multidisciplinary approach and close collaboration among surgeons, anesthesiologists and cardiologists is required, especially when the surgical procedure cannot be postponed. The "bridging" pharmacological protocol was safe and effective after laparoscopic gastrectomy for carcinoma.

AB - Background: An increasing number of patients receive dual antiplatelet therapy following percutaneous coronary interventions. The management of these patients is controversial when urgent noncardiac surgery is required, considering the serious cardiological consequences if such drugs are withdrawn and a high risk of bleeding if they are continued. "Bridging" antiplatelet therapy with tirofiban, a short-acting glycoprotein IIb/IIIa receptor blocker, was used to manage a patient recently implanted with a drug-eluting stent and still on dual antiplatelet therapy, who underwent laparoscopic gastrectomy for gastric carcinoma. Methods Therapy with prasugrel was discontinued 5 days before the surgery and intravenous infusion of tirofiban was started at a dose of 0.4 ìg Kg. 1 min. 1 over 30 min, followed by 0.1 ìg Kg. 1 min. 1. The infusion was stopped 6 h before the surgery. Two hours after the surgical procedure, the same treatment schedule with tirofiban already given preoperatively, including the 30 min bolus, was applied. Prasugrel therapy was resumed 180 h after the surgery. Results: The postoperative course was uneventful. No bleeding or thrombotic events occurred, and the patient was safely discharged home 2 weeks after the surgical procedure. Conclusions There is a lack of precise guidelines for patients recently implanted with drug-eluting stents. A multidisciplinary approach and close collaboration among surgeons, anesthesiologists and cardiologists is required, especially when the surgical procedure cannot be postponed. The "bridging" pharmacological protocol was safe and effective after laparoscopic gastrectomy for carcinoma.

KW - Drug-eluting stent

KW - Dual antiplatelet therapy

KW - Intraoperative bleeding

KW - Laparoscopic gastrectomy

KW - Stent thrombosis

UR - http://www.scopus.com/inward/record.url?scp=84870439528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870439528&partnerID=8YFLogxK

U2 - 10.1007/s10353-012-0158-8

DO - 10.1007/s10353-012-0158-8

M3 - Article

AN - SCOPUS:84870439528

VL - 44

SP - 341

EP - 344

JO - Acta Chirurgica Austriaca

JF - Acta Chirurgica Austriaca

SN - 0001-544X

IS - 5

ER -